You are here

Praluent

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

Regeneron’s Praluent May See Gradual Increase in 2017 Demand

Market Realist

Flag link:

Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics

Sanofi and Regeneron's Praluent safely smacks LDL in high-risk diabetics

Fierce Pharma

LDL cholesterol

Flag link:

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Yahoo

Flag link:

3 Big Biotech Stocks With Big-Time Catalysts

3 Big Biotech Stocks With Big-Time Catalysts

Motley Fool

Flag link:

Sanofi confident in case to overturn Praluent ban

Sanofi confident in case to overturn Praluent ban

BioPharma Dive

Flag link:

Sanofi, Regeneron win a crucial stay of execution on Praluent

Sanofi, Regeneron win a crucial stay of execution on Praluent

Endpoints

Flag link:

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

Medical Marketing and Media

PCSK9 inhibitors

Flag link:

Regeneron CEO says Amgen not putting patients first in patent dispute

Regeneron CEO says Amgen not putting patients first in patent dispute

Yahoo/Reuters

Flag link:

Judge’s unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake

Judge’s unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake

Marketwatch

Flag link:

Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection

Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection

Yahoo

Flag link:

Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales

Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales

Bloomberg

Flag link:

Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent ruling

Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent ruling

Fierce Pharma

PCSK9 inhibitors

Flag link:

Amgen, Regeneron May Yet Get Rich From Their Cholesterol Drugs

Amgen, Regeneron May Yet Get Rich From Their Cholesterol Drugs

Seeking Alpha

Flag link:

No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent

No early success for Regeneron, Sanofi in PhIII outcomes study for PCSK9 drug Praluent

Endpoints

PCSK9 inhibitors

Flag link:

These pricey cholesterol drugs aren’t selling. And that has the biotech industry sweating

These pricey cholesterol drugs aren’t selling. And that has the biotech industry sweating

Stat

PCSK9 inhibitors

Flag link:

Amgen, Sanofi and Regeneron trot out new PCSK9 data at European heart meeting

Amgen, Sanofi and Regeneron trot out new PCSK9 data at European heart meeting

Fierce Pharma

PCSK9 inhibitors

Flag link:

These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year

These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year

Motley Fool

PCSK9 inhibitors

Flag link:

Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA

Are PCSK9 meds worth the cost? Only if Amgen, Sanofi and Regeneron slash prices by two-thirds: JAMA

Fierce Pharma

PCSK9 inhibitors

Flag link:

Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says

Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says

Bloomberg

Flag link:

Pfizer, Amgen, Regeneron Pharmaceuticals: How the PCSK9 Market is Evolving

Pfizer, Amgen, Regeneron Pharmaceuticals: How the PCSK9 Market is Evolving

Bidness, ETC

PCSK9 inhibitors

Flag link: